S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
NASDAQ:KZR

Kezar Life Sciences (KZR) Stock Price, News & Analysis

$0.90
+0.01 (+1.12%)
(As of 03/27/2024 ET)
Today's Range
$0.85
$0.91
50-Day Range
$0.80
$1.05
52-Week Range
$0.67
$3.66
Volume
560,244 shs
Average Volume
904,810 shs
Market Capitalization
$65.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Kezar Life Sciences MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
1,118.2% Upside
$11.00 Price Target
Short Interest
Bearish
4.64% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.72mentions of Kezar Life Sciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.19 out of 5 stars

Medical Sector

172nd out of 939 stocks

Pharmaceutical Preparations Industry

67th out of 435 stocks

KZR stock logo

About Kezar Life Sciences Stock (NASDAQ:KZR)

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

KZR Stock Price History

KZR Stock News Headlines

Buy Friday, Sell Monday, No Exceptions
Every week traders grind it out Monday through Friday… But neglect trading Friday to Monday… Or… “over the weekend” As one professional trader explains, trading over the weekend is one of the most forgiving strategies you can use today. It allows him to sidestep a lot of the midweek volatility. Yet, gives him the opportunity to target some of the markets biggest stock moves. Just recently, he posted a trade on Nordstrom… The trade was published at 3pm on a Friday afternoon and by Monday morning the trade more than doubled.
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Kezar Life Sciences, Inc. (KZR)
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
Kezar Life Sciences Inc.
3 Penny Stocks Poised for an Unbelievable 1,000% Jump
Kezar Life Sciences Inc KZR
KZR Jan 2025 17.500 call
Analyst Expectations for Kezar Life Sciences's Future
See More Headlines
Receive KZR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KZR
Fax
N/A
Employees
58
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$20.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+1,118.2%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-101,870,000.00
Pretax Margin
-1,455.29%

Debt

Sales & Book Value

Annual Sales
$7 million
Book Value
$2.58 per share

Miscellaneous

Free Float
67,050,000
Market Cap
$65.74 million
Optionable
Not Optionable
Beta
0.48
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives


KZR Stock Analysis - Frequently Asked Questions

Should I buy or sell Kezar Life Sciences stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" KZR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KZR, but not buy additional shares or sell existing shares.
View KZR analyst ratings
or view top-rated stocks.

What is Kezar Life Sciences' stock price target for 2024?

3 brokers have issued 12-month target prices for Kezar Life Sciences' stock. Their KZR share price targets range from $2.00 to $20.00. On average, they predict the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 1,118.2% from the stock's current price.
View analysts price targets for KZR
or view top-rated stocks among Wall Street analysts.

How have KZR shares performed in 2024?

Kezar Life Sciences' stock was trading at $0.9474 at the beginning of the year. Since then, KZR shares have decreased by 4.7% and is now trading at $0.9030.
View the best growth stocks for 2024 here
.

When is Kezar Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our KZR earnings forecast
.

How were Kezar Life Sciences' earnings last quarter?

Kezar Life Sciences, Inc. (NASDAQ:KZR) released its earnings results on Tuesday, November, 9th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.02.

What other stocks do shareholders of Kezar Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL).

When did Kezar Life Sciences IPO?

Kezar Life Sciences (KZR) raised $70 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.

Who are Kezar Life Sciences' major shareholders?

Kezar Life Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Avidity Partners Management LP (6.91%), Vanguard Group Inc. (4.21%), Vanguard Group Inc. (4.21%), Granahan Investment Management LLC (2.62%), Northern Trust Corp (0.75%) and Goldman Sachs Group Inc. (0.61%). Insiders that own company stock include Franklin M Berger, Michael Kauffman and Morningside Venture Investment.
View institutional ownership trends
.

How do I buy shares of Kezar Life Sciences?

Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KZR) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners